Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $41.56 Consensus Target Price from Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have been assigned an average recommendation of “Moderate Buy” from the eleven analysts that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $44.50.

Several analysts have issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Wednesday, January 21st. Barclays lifted their price objective on Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a report on Wednesday, December 17th. Stifel Nicolaus restated a “buy” rating and issued a $68.00 price objective (up from $58.00) on shares of Celldex Therapeutics in a research note on Thursday, February 26th. Finally, The Goldman Sachs Group increased their target price on shares of Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a research report on Monday.

Hedge Funds Weigh In On Celldex Therapeutics

A number of large investors have recently made changes to their positions in CLDX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Celldex Therapeutics by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after purchasing an additional 680 shares in the last quarter. Millennium Management LLC boosted its stake in Celldex Therapeutics by 327.3% in the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock worth $7,259,000 after purchasing an additional 306,330 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Celldex Therapeutics by 12.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock valued at $2,383,000 after buying an additional 14,979 shares in the last quarter. AlphaQuest LLC grew its holdings in Celldex Therapeutics by 7.0% during the 2nd quarter. AlphaQuest LLC now owns 12,956 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 844 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its position in shares of Celldex Therapeutics by 171.7% during the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 881 shares during the period.

Celldex Therapeutics Stock Up 2.1%

CLDX opened at $29.54 on Thursday. Celldex Therapeutics has a twelve month low of $14.40 and a twelve month high of $31.31. The company’s 50-day moving average price is $25.86 and its two-hundred day moving average price is $25.61. The stock has a market cap of $1.97 billion, a price-to-earnings ratio of -7.59 and a beta of 1.17.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.22). Celldex Therapeutics had a negative return on equity of 41.67% and a negative net margin of 3,446.88%.The company had revenue of $0.12 million during the quarter, compared to the consensus estimate of $1.53 million. As a group, sell-side analysts anticipate that Celldex Therapeutics will post -2.48 earnings per share for the current year.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.